Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HAILEY FE 1.5/30 vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy,Acne vulgaris (off-label for females ≥15 years),Irregular menstruation (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol: primarily metabolized by CYP3A4 via hydroxylation; undergoes first-pass metabolism in the liver and gut wall. Norethindrone: primarily metabolized via reduction followed by glucuronide conjugation; some involvement of CYP3A4.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Ethinyl estradiol: ~97-98% bound to albumin; norethindrone: ~95% bound to albumin and sex hormone-binding globulin (SHBG).
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Ethinyl estradiol: ~2-4 L/kg; norethindrone: ~2-4 L/kg. Reflects extensive tissue distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Ethinyl estradiol: 40-50% due to first-pass metabolism; norethindrone: 50-70% due to first-pass metabolism.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dosage adjustment required for renal impairment. Use with caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in acute hepatitis, severe cirrhosis (Child-Pugh C), or liver tumors. For mild hepatic impairment (Child-Pugh A), no adjustment; use with caution.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not indicated for premenarchal girls. For postmenarchal adolescents, same dosing as adults.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for postmenopausal women due to higher risk of thromboembolic events and lack of efficacy for contraception in this population.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially in women over 35) and with heavy smoking (≥15 cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Risk of thromboembolic disorders and thrombotic events (e.g., MI, stroke, DVT, PE),Increased risk of cervical cancer and breast cancer (controversial),Hepatic neoplasia (benign and malignant),Gallbladder disease,Hypertension,Impaired liver function,Carbohydrate and lipid effects,Headache/migraine,Bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Depression,Contact lens intolerance,Fluid retention
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Current or history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer or personal history of breast cancer,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior OCP use,Hepatic adenomas or carcinomas,Known or suspected pregnancy,Hypersensitivity to any component,Major surgery with prolonged immobilization,Smoking in women over 35 years old,Current or history of migraine with focal aura if >35 years old,Current or history of hypertension with vascular disease
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels but effect is not clinically significant; no restriction. Iron absorption may be enhanced by vitamin C (e.g., citrus); avoid taking with dairy or antacids that reduce iron absorption, separate by at least 2 hours if needed.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Category X: Contraindicated in pregnancy. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second/third trimesters: Associated with fetal adrenal suppression, hepatic dysfunction, and masculinization of female fetuses. Discontinue immediately if pregnancy occurs.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Excreted in breast milk in low amounts (estrogen M/P ratio ~0.2; progestin M/P ~0.3). Theoretical risk of reduced milk production and infant jaundice. Use only if benefits outweigh risks; consider alternative contraception.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Contraindicated in pregnancy. No indication for use; pharmacokinetic changes (increased clearance, protein binding changes) are irrelevant as use is prohibited.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
HAILEY FE 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 µg and norethindrone 1.5 mg, with iron supplementation (ferrous fumarate 75 mg). The iron component is not part of the contraceptive effect but helps maintain iron stores during menstruation. It is typically taken for 21 active pills followed by 7 placebo pills (containing iron). Administer consistently at the same time daily to maintain hormone levels and minimize breakthrough bleeding. Monitor for elevated blood pressure, thromboembolic events, and hepatic adenoma. Smoking increases cardiovascular risk; avoid in women over 35 who smoke. Efficacy may be reduced with hepatic enzyme-inducing drugs (e.g., rifampin, certain anticonvulsants).
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet daily at the same time each day, even if you do not have sex.,The first 21 pills are active hormones; the last 7 pills (green) contain iron and are placebos.,If you miss a pill, follow the package instructions: take the missed pill as soon as remembered, and use backup contraception if you miss more than one.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,Smoking while on this pill increases risk of serious cardiovascular events; do not smoke.,Contact your healthcare provider if you experience leg pain, chest pain, sudden severe headache, or visual changes.,HAILEY FE does not protect against HIV or other sexually transmitted infections; use condoms for protection.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.,If you have severe vomiting or diarrhea, use additional contraception.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HAILEY FE 1.5/30 vs ALTAVERA, answered by our medical review team.
HAILEY FE 1.5/30 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HAILEY FE 1.5/30 and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HAILEY FE 1.5/30 is: One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HAILEY FE 1.5/30 and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HAILEY FE 1.5/30 is classified as Category C. Category X: Contraindicated in pregnancy. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second/third trimesters: Ass. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.